Clinical Trials Logo

Mesothelioma clinical trials

View clinical trials related to Mesothelioma.

Filter by:

NCT ID: NCT03319537 Recruiting - Mesothelioma Clinical Trials

Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma

Start date: October 5, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test any good and bad effects of activity pevonedistat taken alone, and also to test the safety of pevonedistat in combination with standard chemotherapy, pemetrexed/cisplatin.

NCT ID: NCT03290183 Recruiting - Thymoma Clinical Trials

Confocal Laser Endomicroscopy in Pleural Malignancies

Start date: August 28, 2017
Phase: N/A
Study type: Observational

To date, the different biopsy methods, such as CT-guided pleural biopsy, mediastinal biopsy, endosonography and thoracoscopy have their limitations in diagnosing pleural malignancies, such as mesothelioma. Sampling errors frequently occur resulting in the common histological finding of 'non-specific pleuritic/fibrosis', which presents a great uncertainty for clinicians and patients. Confocal laser endomicroscopy (CLE) provides real-time imaging on a cellular level, however data of CLE in pleural malignancies are lacking.

NCT ID: NCT03269227 Recruiting - Clinical trials for Malignant Pleural Mesothelioma

Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma

MesoRT
Start date: August 14, 2017
Phase: N/A
Study type: Interventional

This is a monocentric prospective study of radiotherapy using accelerated hypofractionation with Tomotherapy in Malignant Pleural Mesothelioma (MPM) patients after pleurectomy / decortication (P / D) or biopsy. The treatment will be delivered using Tomotherapy, that allows to adopt dose accelerated hypofraction criteria. Treatment duration is 5 consecutive days.

NCT ID: NCT03228537 Not yet recruiting - Clinical trials for Stage III Pleural Malignant Mesothelioma AJCC v7

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Start date: November 3, 2017
Phase: Phase 1
Study type: Interventional

This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy in treating patients with stage I-III pleural malignant mesothelioma. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, pemetrexed disodium, and cisplatin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving atezolizumab after surgery may kill any remaining tumor cells.

NCT ID: NCT03213301 Recruiting - Clinical trials for Malignant Pleural Mesothelioma, Advanced

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

Start date: September 28, 2017
Phase: Phase 2
Study type: Interventional

Aim of this study is to provide the "proof of concept" of efficacy and tolerability of lurbinectedin monotherapy in progressive malignant mesotheliomas.

NCT ID: NCT03212404 Recruiting - Clinical trials for Head and Neck Cancer

Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers

Start date: September 20, 2017
Phase: Phase 1
Study type: Interventional

CK-301 is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objective of this study is to assess the safety, tolerability and preliminary efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.

NCT ID: NCT03210298 Recruiting - Colorectal Cancer Clinical Trials

International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

PIPACRegis
Start date: January 2016
Phase: N/A
Study type: Observational [Patient Registry]

Multicentric, international, web-based prospective documentation of the indications and results of Pressurized Aerosol Chemotherapy (so-called PIPAC or PITAC) for treating malignant pleural and peritoneal diseases. Indication is decided by the treating physician. There are no predefined inclusion or exclusion criteria.

NCT ID: NCT03207347 Not yet recruiting - Clinical trials for Renal Cell Carcinoma

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Start date: January 2018
Phase: Phase 2
Study type: Interventional

This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.

NCT ID: NCT03177668 Recruiting - Clinical trials for Malignant Pleural Mesothelioma

Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma

Start date: June 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to examine tolerability, safety, and pharmacokinetics of YS110 intravenous administration in patients with malignant pleural mesothelioma and to preliminarily examine the anti-tumor effect of YS110.

NCT ID: NCT03175172 Recruiting - Clinical trials for Malignant Pleural Mesothelioma

Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM

Start date: June 15, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether CRS-207 with pembrolizumab is safe and effective in adults with MPM who have failed prior anti-cancer therapy.